



## NOTICE TO MEMBERS

No. 2008 - 021

February 21, 2008

### **FINAL CONTRACT ADJUSTMENT Axcan Pharma Inc. (AXP) - Acquisition**

**THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF CANADIAN DERIVATIVES CLEARING CORPORATION ("CDCC") MEMBERS AND BOURSE DE MONTRÉAL INC. (THE "BOURSE") APPROVED PARTICIPANTS. THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ACQUISITION. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.**

The Bourse and CDCC wish to inform you that Axcan Pharma Inc. ("Axcan") has received shareholders and all regulatory approvals necessary to consummate the proposed acquisition by an affiliate of TPG Capital. Pursuant to the terms of this agreement, Axcan common shareholders will receive a cash amount of US \$23.35 per common share, as announced in the Bourse Circular n° 184-2007 and CDCC Notice n°2007-126 dated December 3, 2007. The transaction is expected to close on February 25, 2008.

The Bourse and CDCC did not adjust the option series since the option contracts on Axcan had no open interest. All series on this class have been removed.

For further information, please contact Louise Leclair, Trading Systems Analyst Market Operations, Bourse de Montréal Inc. at (514) 871-3526. CDCC clearing members may contact the Operations Department.

Michel Favreau  
Senior Vice-President and Chief Clearing Officer

---

<b>Canadian Derivatives Clearing Corporation</b>	
65 Queen Street West	800 Victoria Square
Suite 700	3 <sup>rd</sup> Floor
Toronto, Ontario	Montréal, Québec
M5H 2M5	H4Z 1A9
Tel. : 416-367-2463	Tel. : 514-871-3545
Fax : 416-367-2473	Fax : 514-871-3530

[www.cdcc.ca](http://www.cdcc.ca)